Safety and efficacy of a rapid-acting topical 4% lidocaine gel in a unique drug delivery system

Leslie S. Baumann, Lisa Grunebaum, Mohamed L. Elsaie, Jennifer Murdock, Eric Jablonka, Kristian Figueras, Michaela Bell

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Ideally, topical anesthetics should provide rapid analgesic action without causing toxic blood levels of lidocaine or other side effects. Various formulations of lidocaine as a topical anesthetic have been tested and are currently on the market. Here, the authors report on a topical lidocaine with a novel delivery system that provides a rapid onset of action without toxic plasma levels of lidocaine. Objective: Study 1 assessed the time needed for a topical 4% lidocaine gel with a unique drug delivery system to produce optimal anesthetic effects. Study 2 assessed lidocaine plasma concentrations and assessed the time to maximal anesthetic effect. Methods: In both studies, subjects received six botulinum toxin type A injections for crow's feet wrinkles in six separate zones in the lateral periocular regions bilaterally. The first injection was administered in the absence of topical 4% lidocaine gel. Gel was then applied to the remaining five zones and injections were given at set time points out to 45 minutes. In study 2, blood samples were taken from baseline to 60 minutes. Results: Significant anesthetic effect with topical 4% lidocaine gel was attained without occlusion in approximately 25-30 minutes. However, optimum effects were observed between 35-40 minutes after application. Additionally, topical 4% lidocaine, when used appropriately, did not produce lidocaine plasma levels associated with toxicity. Conclusion: Topical 4% lidocaine gel with a unique drug delivery system produces significant anesthesia without occlusion in approximately 25-30 minutes with optimal effects observed between 35-40 minutes after application. Topical 4% lidocaine gel can be used effectively and safely as a topical anesthetic in the physician's office.

Original languageEnglish
Pages (from-to)1500-1504
Number of pages5
JournalJournal of Drugs in Dermatology
Volume9
Issue number12
StatePublished - Dec 1 2010

Fingerprint

Drug Delivery Systems
Lidocaine
Gels
Safety
Local Anesthetics
Anesthetics
Injections
Toxic Actions
Crows
Physicians' Offices
Type A Botulinum Toxins
Poisons
Analgesics
Foot
Anesthesia

ASJC Scopus subject areas

  • Dermatology

Cite this

Baumann, L. S., Grunebaum, L., Elsaie, M. L., Murdock, J., Jablonka, E., Figueras, K., & Bell, M. (2010). Safety and efficacy of a rapid-acting topical 4% lidocaine gel in a unique drug delivery system. Journal of Drugs in Dermatology, 9(12), 1500-1504.

Safety and efficacy of a rapid-acting topical 4% lidocaine gel in a unique drug delivery system. / Baumann, Leslie S.; Grunebaum, Lisa; Elsaie, Mohamed L.; Murdock, Jennifer; Jablonka, Eric; Figueras, Kristian; Bell, Michaela.

In: Journal of Drugs in Dermatology, Vol. 9, No. 12, 01.12.2010, p. 1500-1504.

Research output: Contribution to journalArticle

Baumann, LS, Grunebaum, L, Elsaie, ML, Murdock, J, Jablonka, E, Figueras, K & Bell, M 2010, 'Safety and efficacy of a rapid-acting topical 4% lidocaine gel in a unique drug delivery system', Journal of Drugs in Dermatology, vol. 9, no. 12, pp. 1500-1504.
Baumann LS, Grunebaum L, Elsaie ML, Murdock J, Jablonka E, Figueras K et al. Safety and efficacy of a rapid-acting topical 4% lidocaine gel in a unique drug delivery system. Journal of Drugs in Dermatology. 2010 Dec 1;9(12):1500-1504.
Baumann, Leslie S. ; Grunebaum, Lisa ; Elsaie, Mohamed L. ; Murdock, Jennifer ; Jablonka, Eric ; Figueras, Kristian ; Bell, Michaela. / Safety and efficacy of a rapid-acting topical 4% lidocaine gel in a unique drug delivery system. In: Journal of Drugs in Dermatology. 2010 ; Vol. 9, No. 12. pp. 1500-1504.
@article{f979d49b9b8e481f972ac23d374ef791,
title = "Safety and efficacy of a rapid-acting topical 4{\%} lidocaine gel in a unique drug delivery system",
abstract = "Background: Ideally, topical anesthetics should provide rapid analgesic action without causing toxic blood levels of lidocaine or other side effects. Various formulations of lidocaine as a topical anesthetic have been tested and are currently on the market. Here, the authors report on a topical lidocaine with a novel delivery system that provides a rapid onset of action without toxic plasma levels of lidocaine. Objective: Study 1 assessed the time needed for a topical 4{\%} lidocaine gel with a unique drug delivery system to produce optimal anesthetic effects. Study 2 assessed lidocaine plasma concentrations and assessed the time to maximal anesthetic effect. Methods: In both studies, subjects received six botulinum toxin type A injections for crow's feet wrinkles in six separate zones in the lateral periocular regions bilaterally. The first injection was administered in the absence of topical 4{\%} lidocaine gel. Gel was then applied to the remaining five zones and injections were given at set time points out to 45 minutes. In study 2, blood samples were taken from baseline to 60 minutes. Results: Significant anesthetic effect with topical 4{\%} lidocaine gel was attained without occlusion in approximately 25-30 minutes. However, optimum effects were observed between 35-40 minutes after application. Additionally, topical 4{\%} lidocaine, when used appropriately, did not produce lidocaine plasma levels associated with toxicity. Conclusion: Topical 4{\%} lidocaine gel with a unique drug delivery system produces significant anesthesia without occlusion in approximately 25-30 minutes with optimal effects observed between 35-40 minutes after application. Topical 4{\%} lidocaine gel can be used effectively and safely as a topical anesthetic in the physician's office.",
author = "Baumann, {Leslie S.} and Lisa Grunebaum and Elsaie, {Mohamed L.} and Jennifer Murdock and Eric Jablonka and Kristian Figueras and Michaela Bell",
year = "2010",
month = "12",
day = "1",
language = "English",
volume = "9",
pages = "1500--1504",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "12",

}

TY - JOUR

T1 - Safety and efficacy of a rapid-acting topical 4% lidocaine gel in a unique drug delivery system

AU - Baumann, Leslie S.

AU - Grunebaum, Lisa

AU - Elsaie, Mohamed L.

AU - Murdock, Jennifer

AU - Jablonka, Eric

AU - Figueras, Kristian

AU - Bell, Michaela

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Background: Ideally, topical anesthetics should provide rapid analgesic action without causing toxic blood levels of lidocaine or other side effects. Various formulations of lidocaine as a topical anesthetic have been tested and are currently on the market. Here, the authors report on a topical lidocaine with a novel delivery system that provides a rapid onset of action without toxic plasma levels of lidocaine. Objective: Study 1 assessed the time needed for a topical 4% lidocaine gel with a unique drug delivery system to produce optimal anesthetic effects. Study 2 assessed lidocaine plasma concentrations and assessed the time to maximal anesthetic effect. Methods: In both studies, subjects received six botulinum toxin type A injections for crow's feet wrinkles in six separate zones in the lateral periocular regions bilaterally. The first injection was administered in the absence of topical 4% lidocaine gel. Gel was then applied to the remaining five zones and injections were given at set time points out to 45 minutes. In study 2, blood samples were taken from baseline to 60 minutes. Results: Significant anesthetic effect with topical 4% lidocaine gel was attained without occlusion in approximately 25-30 minutes. However, optimum effects were observed between 35-40 minutes after application. Additionally, topical 4% lidocaine, when used appropriately, did not produce lidocaine plasma levels associated with toxicity. Conclusion: Topical 4% lidocaine gel with a unique drug delivery system produces significant anesthesia without occlusion in approximately 25-30 minutes with optimal effects observed between 35-40 minutes after application. Topical 4% lidocaine gel can be used effectively and safely as a topical anesthetic in the physician's office.

AB - Background: Ideally, topical anesthetics should provide rapid analgesic action without causing toxic blood levels of lidocaine or other side effects. Various formulations of lidocaine as a topical anesthetic have been tested and are currently on the market. Here, the authors report on a topical lidocaine with a novel delivery system that provides a rapid onset of action without toxic plasma levels of lidocaine. Objective: Study 1 assessed the time needed for a topical 4% lidocaine gel with a unique drug delivery system to produce optimal anesthetic effects. Study 2 assessed lidocaine plasma concentrations and assessed the time to maximal anesthetic effect. Methods: In both studies, subjects received six botulinum toxin type A injections for crow's feet wrinkles in six separate zones in the lateral periocular regions bilaterally. The first injection was administered in the absence of topical 4% lidocaine gel. Gel was then applied to the remaining five zones and injections were given at set time points out to 45 minutes. In study 2, blood samples were taken from baseline to 60 minutes. Results: Significant anesthetic effect with topical 4% lidocaine gel was attained without occlusion in approximately 25-30 minutes. However, optimum effects were observed between 35-40 minutes after application. Additionally, topical 4% lidocaine, when used appropriately, did not produce lidocaine plasma levels associated with toxicity. Conclusion: Topical 4% lidocaine gel with a unique drug delivery system produces significant anesthesia without occlusion in approximately 25-30 minutes with optimal effects observed between 35-40 minutes after application. Topical 4% lidocaine gel can be used effectively and safely as a topical anesthetic in the physician's office.

UR - http://www.scopus.com/inward/record.url?scp=79955049285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955049285&partnerID=8YFLogxK

M3 - Article

C2 - 21120257

AN - SCOPUS:79955049285

VL - 9

SP - 1500

EP - 1504

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 12

ER -